Danish pharmaceutical firm Novo Nordisk A/S (NYSE:NVO) announced plans to invest approximately $1.20 billion (8.5 billion ...
Powerful weight-loss drugs are expanding use of U.S. health care as patients starting prescriptions are diagnosed with ...
The fundamentals of Novo and Lilly do look robust, but it is always wise to avoid putting all of your eggs in one basket.
The German Diabetes Society (DDG) issued a warning concerning a rise in pregnancies among women using injectable medications ...
The Danish Medicines Agency said it would ask European authorities to review two new studies that point to a link between ...
Copenhagen: Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight loss treatments Ozempic and Wegovy, said Monday it was investing ...
Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, said Monday it was ...
How Trump's new Health Secretary plans to restrict the use of the most popular anti-obesity drug - The method of drastically ...
Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, which have gained ...
Some people are not taking weight-loss medications responsibly, the physician says, and don't realize their full implications ...
8h
The secret agent in the decrease might be semaglutide, a GLP-1 receptor agonist that fuels popular weight loss drugs like ...
He cited a study that found that although the U.S. has the costliest healthcare system in the world, it ranks 42nd in life ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback